HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

SO1861

enhances cytotoxicity of dianthin-related immunotoxins; isolated from Saponaria officinalis; structure in first source

Networked: 6 relevant articles (2 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Carbohydrates: 22023
- Glycosides: 2119
  - Saponins: 2867
    - SO1861: 6

Experts

1.	Fuchs, Hendrik: 2 articles (11/2017 - 09/2017)
2.	Weng, Alexander: 2 articles (11/2017 - 09/2017)
3.	Bhargava, Cheenu: 1 article (11/2017)
4.	Dürkop, Horst: 1 article (11/2017)
5.	Melzig, Matthias F: 1 article (11/2017)
6.	Zhao, Xiangli: 1 article (11/2017)
7.	Boyd, Andrew W: 1 article (09/2017)
8.	Day, Bryan W: 1 article (09/2017)
9.	Furness, Sebastian G B: 1 article (09/2017)
10.	Gilabert-Oriol, Roger: 1 article (09/2017)

Related Diseases

1.	Non-Hodgkin Lymphoma (Lymphosarcoma) 10/13/2022 - "Correction: Panjideh et al. Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861. " 01/01/2022 - "Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861."
2.	Lymphoma (Lymphomas) 01/01/2022 - "Taken together, our results substantially contribute to the development of a combination therapy with SO1861 as a platform technology to enhance the efficacy of therapeutic antibody-toxin conjugates in lymphoma and leukemia."
3.	Leukemia 01/01/2022 - "Taken together, our results substantially contribute to the development of a combination therapy with SO1861 as a platform technology to enhance the efficacy of therapeutic antibody-toxin conjugates in lymphoma and leukemia."
4.	Neoplasms (Cancer) 01/01/2023 - "Treatment of mice bearing prostate tumors with a combination of hD7-1(VL-VH)-PE24mutΔREDLK plus SO1861 resulted in inhibition of tumor growth and enhanced overall survival compared to the monotherapies. " 11/01/2017 - "Monotherapy of BxPC-3 xenografts in CD-1 nude mice led to a 51.7% average reduction in tumor size (40.8 mm3 ) when compared to placebo; however, combined treatment with SO1861 resulted in a more than 13-fold better efficacy (3.0 mm3 average tumor size) with complete regression in 80% of cases. " 01/01/2022 - "In vivo imaging in a xenograft model of B-cell lymphoma in mice revealed that ObiDi/SO1861 efficiently prevents tumor growth (51.4% response rate) compared to the monotherapy with ObiDi (25.9%) and non-conjugated obinutuzumab (20.7%). "
5.	Prostatic Neoplasms (Prostate Cancer) 01/01/2023 - "The endosomal entrapment of non-toxic anti-PSMA immunotoxins followed by enhanced endosomal escape by SO1861 provides new therapeutic options in the future management of prostate cancer." 01/01/2023 - "Synergistic Cytotoxicity of a Toxin Targeting the Epidermal Growth Factor Receptor and the Glycosylated Triterpenoid SO1861 in Prostate Cancer." 01/01/2023 - "Enhanced cytotoxicity of a Pseudomonas Exotoxin A based immunotoxin against prostate cancer by addition of the endosomal escape enhancer SO1861."

Related Drugs and Biologics

1.	obinutuzumab
2.	Immunotoxins (Immunotoxin)
3.	Triterpenes
4.	ErbB Receptors (EGF Receptor)
5.	Immunoconjugates (Immunoconjugate)
6.	Glycosides
7.	Exotoxins

Related Therapies and Procedures

1.	Therapeutics